Financial Performance - The company's operating revenue for 2023 was CNY 190,144,196.65, representing a 9.14% increase compared to CNY 174,221,005.91 in 2022[21]. - The net profit attributable to shareholders decreased by 39.60% to CNY 38,774,331.63 from CNY 64,198,283.70 in the previous year[21]. - The net cash flow from operating activities fell by 51.67% to CNY 32,819,923.92, down from CNY 67,913,773.25 in 2022[22]. - The basic earnings per share decreased by 42.86% to CNY 0.36 from CNY 0.63 in 2022[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 46.37% to CNY 24,001,855.26 from CNY 44,756,410.48 in 2022[21]. - The total assets decreased by 3.26% to CNY 1,128,472,545.63 from CNY 1,166,487,618.62 in the previous year[22]. - The net assets attributable to shareholders decreased by 3.19% to CNY 1,085,840,605.47 at the end of 2023, down from CNY 1,121,631,273.84 at the end of 2022[22]. - The company reported a significant non-operating income of 14.77 million yuan, down from 19.44 million yuan in the previous year[29]. - The company achieved operating revenue of CNY 190.14 million in 2023, a year-on-year increase of 9.14%[34]. - The sales revenue of antivenom serum reached 155.87 million yuan, growing by 11.31% compared to the previous year[34]. Research and Development - Research and development expenses accounted for 15.99% of operating revenue, an increase of 7.12 percentage points from 8.87% in 2022[23]. - The company increased its research and development (R&D) investment to ¥30,411,906.84 in the current year, a 96.75% increase from ¥15,457,131.29 in the previous year[79]. - The company is actively developing new products, including a rapid diagnostic reagent for cobra venom, which has entered the clinical trial phase[37]. - The company is advancing its innovative drug development project for anti-viper snake serum, which is expected to enter phase II clinical trials in January 2024[78]. - The company has developed unique emergency rescue products, including antivenoms for various snake bites, which are the only ones produced domestically[87]. - The company has established a significant technological advantage in the production of antivenoms, supported by proprietary technologies and patents in various critical processes[88]. - The company is conducting clinical research on a rapid diagnostic reagent for snake venom, with a total investment of ¥1,350,000 in the current period[82]. - The company is working on multiple projects, including anti-rabies serum and anti-bee venom serum, with significant investments and progress in clinical research stages[81]. Market Position and Strategy - The company specializes in the research, development, production, and sales of antivenom and antitoxin drugs, covering the entire industry chain from new drug development to sales[38]. - The company is currently the only producer of antivenom serum for snake bites in China, indicating a unique market position[55]. - The antivenom products are listed in the World Health Organization's essential medicines list, significantly reducing the incidence and mortality rates of snake bites[39]. - The company plans to enhance promotional efforts to increase the coverage of antivenom serum products, aiming to reduce fatalities and disabilities caused by snake bites[58]. - The company is positioned in the biopharmaceutical sector, specifically in the antivenom and antitoxin subfield, which is characterized by high innovation and significant market potential[49]. - The biopharmaceutical industry in China is experiencing rapid growth, driven by increasing healthcare spending and expanding insurance coverage, indicating a promising market outlook[50]. - The company plans to continue expanding its market presence and product offerings, particularly in the anti-snake venom serum product line[24]. Corporate Governance - The company has not violated decision-making procedures for external guarantees[8]. - The board of directors was fully present at the meeting to approve the annual report[5]. - The company has not engaged in labor outsourcing, maintaining a fully in-house workforce[196]. - The company has a clear and structured compensation policy that includes competitive salaries and performance incentives to motivate employees[194]. - The company maintained independence from its controlling shareholder in terms of assets, personnel, finance, and operations, with no non-operating fund occupation[162]. - The company held two shareholder meetings and seven board meetings during the reporting period, ensuring compliance with legal and regulatory requirements[160]. - The company appointed two new independent directors during the reporting period, enhancing governance and oversight[161]. - The company emphasized investor relations, utilizing various channels for communication and feedback from shareholders[162]. Risks and Challenges - The company faces risks related to potential price controls or competition that could lead to reduced sales prices for its products[95]. - The company faces risks related to a single product structure, primarily relying on snake antivenom and tetanus immunoglobulin[98]. - There is a risk of market promotion progress falling short of expectations, which could negatively impact product sales[99]. - The company relies on a limited number of suppliers for horses used in the production of its antivenom products, posing a risk of supply shortages[97]. - The company’s antivenom serum products are facing competition from traditional Chinese medicine and other alternative treatments, which may affect market penetration[58]. Future Outlook - The company plans to enhance its competitive edge by upgrading production processes to improve product purity and reduce adverse reactions in the antiserum and antitoxin sector[152]. - The company plans to strengthen market expansion and R&D innovation in 2024, aiming to improve product market application and operational efficiency[156]. - The company will advance the clinical research of antivenom products and rapid diagnostic kits in 2024, including multiple clinical studies and regulatory submissions[157]. - Future guidance suggests a projected revenue growth of approximately 10% for the upcoming fiscal year[170]. - The company is committed to sustainability initiatives, aiming to reduce its carbon footprint by 20% over the next five years[170].

Group 1: Market Overview - The company is the only domestic manufacturer of anti-snake venom serum, which is the only effective treatment for snakebite poisoning [4] - The market for anti-snake venom serum is influenced by factors such as ecological improvements, climate conditions, and natural disasters [4] - There is a lack of precise statistics on the number of snakebite patients each year, but the application level of anti-snake venom serum is gradually improving [4] Group 2: Competitive Landscape - Competing products for anti-snake venom serum include traditional Chinese medicine and folk remedies, which serve different therapeutic purposes [5] - The market share of tetanus immunoglobulin products is dominated by tetanus antitoxin, with anti-snake venom immunoglobulin being significantly cheaper and safer [6][7] - The company is working on academic promotion to increase its market share in the tetanus immunoglobulin market [7] Group 3: Usage and Administration - The number of anti-snake venom serum doses used varies significantly across regions and medical institutions due to differences in patient conditions and treatment practices [6] - Anti-snake venom serum should be administered as soon as possible after a snakebite, with intravenous drip being the recommended method [6] - The application of anti-snake venom serum is expanding in primary healthcare institutions, with increasing usage in community hospitals [8] Group 4: Insurance and Reimbursement - Anti-snake venom serum is included in the "Class A" category of the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance drug catalog [8] - Reimbursement policies for anti-snake venom serum vary by province, city, insurance type, and level of medical institution [8] Group 5: Research and Development - The company is currently developing a rapid diagnostic reagent for snake venom, which is still in the research phase and has not yet been priced [7] - The anti-rabies serum product is undergoing technical improvements and is not yet available for sale [8]

方正证券承销保荐有限责任公司 关于上海赛伦生物技术股份有限公司 公司的部分募集资金存在暂时闲置的情形。 三、本次使用部分暂时闲置募集资金进行现金管理的相关情况 （一）现金管理目的 使用部分暂时闲置募集资金进行现金管理的核查意见 方正证券承销保荐有限责任公司（以下简称"保荐机构"）作为上海赛伦生 物技术股份有限公司（以下简称"公司"或"赛伦生物"）首次公开发行股票并 在科创板上市的保荐机构及持续督导机构，根据《上海证券交易所科创板股票上 市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号—规范运作》《上 市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》以及《科创 板上市公司持续监管办法（试行）》等法律法规及业务规则的规定，就赛伦生物 使用部分暂时闲置募集资金进行现金管理的事项进行了核查，具体情况如下： 一、本次募集资金基本情况 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]204 号）的批准，公司获准向社 会公开发行人民币普通股 2,706 万股，每股面值为 1.00 元，每股发行价格为 33.03 元，公司收到募集 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2024-007 上海赛伦生物技术股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海赛伦生物技术股份有限公司（以下简称"赛伦生物"或"公司"）第三 届董事会第十九次会议和第三届监事会第十四次会议分别审议通过了《关于使用 部分暂时闲置募集资金进行现金管理的议案》，同意在保证不影响公司募集资金 投资计划正常进行的前提下，使用最高不超过人民币 6.3 亿元的暂时闲置募集资 金进行现金管理，用于购买安全性高、流动性好、有保本约定的投资产品（包括 但不限于结构性存款、协定存款、通知存款、定期存款、大额存单、收益凭证等）， 期限不超过 12 个月，自董事会审议通过之日起 12 个月内有效。在上述额度及期 限范围内，公司可以循环滚动使用。公司董事会授权公司管理层在决议有效期、 上述投资额度、投资期限及投资品种内，行使投资决策权并签署相关法律文件， 具体事项由公司财务部负责实施。保荐机构方正证券承销保荐有限 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2024-006 关于实际控制人之一、董事、总经理及部分高级管理人员 增持股份进展的公告 增持计划的基本情况：上海赛伦生物技术股份有限公司（以下简称"公 司"）实际控制人之一、董事、总经理范铁炯先生，及副总经理、董事会秘书成 琼女士，副总经理彭良俊先生，财务总监李绍阳先生（以下简称"增持主体"） 基于对公司未来发展的信心和对公司长期投资价值的认可，同时为增强投资者信 心，维护公司全体股东利益，计划自 2024 年 2 月 26 日起 6 个月内，通过上海证 券交易所系统允许的方式（包括但不限于集中竞价和大宗交易等）增持公司股份， 合计增持金额不低于人民币 380 万元，且不超过人民币 630 万元。具体内容详见 公司 2024 年 2 月 24 日于上海证券交易所网站（www.sse.com.cn）披露的《关于 实际控制人之一、董事、总经理及部分高级管理人员增持股份计划的公告》（公 告编号：2024-003）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海赛伦生 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2024-005 上海赛伦生物技术股份有限公司 关于副总经理离职暨核心技术人员调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海赛伦生物技术股份有限公司（以下简称"公司"）董事会近日收到 董事、副总经理、核心技术人员何毅明先生递交的辞职报告，何毅明先生因年龄 原因申请辞去副总经理一职，辞任后将继续担任公司第三届董事会董事职务，同 时，公司将聘请其担任技术顾问职务。何毅明先生的辞职报告自送达公司董事会 之日起生效。何毅明先生所负责的工作已完成交接，其辞任副总经理一职不会影 响公司核心技术的完整性，不会对公司的研发发展、生产经营活动和业务发展造 成实质性影响。 公司结合副总经理彭良俊先生的任职履历、公司研发与技术发展的需要， 以及其参与核心技术研发的情况等相关因素，经公司第三届董事会第十八次会议 审议通过，认定其为核心技术人员。 截至本公告披露之日，何毅明先生直接持有公司股份 140,000 股，通过上海 赛派投资合伙企业（有限合伙）间接持有公 ...

1 截至本核查意见披露之日，何毅明先生直接持有公司股份 140,000 股，通过 上海赛派投资合伙企业（有限合伙）间接持有公司股份 50,000 股。辞任副总经 理后，何毅明先生将继续遵守《上海证券交易所科创板股票上市规则》等相关法 律法规的规定及公司首次公开发行股票时所作的相关承诺。 （二）参与的研发工作和专利情况 方正证券承销保荐有限责任公司 关于上海赛伦生物技术股份有限公司 副总经理离职暨核心技术人员调整的核查意见 方正证券承销保荐有限责任公司（以下简称"保荐机构"）作为上海赛伦生 物技术股份有限公司（以下简称"公司"或"赛伦生物"）首次公开发行股票并 在科创板上市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板上市公司自律监管指引第 1 号—规范运作》《上海证券 交易所科创板股票上市规则》以及《科创板上市公司持续监管办法（试行）》等 法律法规及业务规则的规定，对赛伦生物副总经理离职暨核心技术人员调整的情 况进行了核查，具体核查情况如下： 一、何毅明先生离职的具体情况 公司董事会近日收到董事、副总经理、核心技术人员何毅明先生递交的辞职 报告，何毅明先生因年龄原因申请辞去 ...

方正证券承销保荐有限责任公司 关于上海赛伦生物技术股份有限公司 首次公开发行战略配售限售股上市流通的核查意见 方正证券承销保荐有限责任公司（以下简称"保荐机构"）作为上海赛伦生 物技术股份有限公司（以下简称"公司"或"赛伦生物"）首次公开发行股票并 在科创板上市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号—规范运作》以及《科创板上市公司持续监管办法（试行）》等 相关规定，对赛伦生物首次公开发行战略配售限售股上市流通事项进行了核查， 情况如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 1 月 25 日出具的《关于同意上海赛 伦生物技术股份有限公司首次公开发行股票注册的批复》（证监许可[2022]204 号），同意公司首次公开发行股票的注册申请。公司首次向社会公众公开发行人 民币普通股（A 股）股票 27,060,000 股，并于 2022 年 3 月 11 日在上海证券交易 所科创板上市，发行完成后股本总数为 108,220,000 股，其中有限售条件流通股 83,456, ...

证券代码：688163 证券简称：赛伦生物 公告编号：2024-004 上海赛伦生物技术股份有限公司 首次公开发行战略配售限售股上市流通公告 一、本次上市流通的限售股类型 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会于 2022 年 1 月 25 日出具的《关于同意上海赛 伦生物技术股份有限公司首次公开发行股票注册的批复》（证监许可【2022】204 号），同意公司首次公开发行股票的注册申请。公司首次向社会公众公开发行人 民币普通股（A 股）股票 27,060,000 股，并于 2022 年 3 月 11 日在上海证券交易 所科创板上市，发行完成后股本总数为 108,220,000 股，其中有限售条件流通股 83,456,396 股，占公司股本总数的 77.12%，无限售条件流通股 24,763,604 股，占 公司股本总数的 22.88%。 重要内容提示： 本次股票上市类型为首发战略配售股份（限售期 24 月）；股票认购方式为 网下，上市股数为 1,211,020 股。本公司确认，上市流通数 ...

证券代码：688163 证券简称：赛伦生物 上海赛伦生物技术股份有限公司投资者关系活动记录表 （2024 年2 月） √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活 □新闻发布会 □路演活动 动类别 □现场参观 □其他 （请文字说明其他活动内容） 嘉实基金 孙晓晖，光大保德信基金 高睿婷 参与单位名称 鹏华基金 蔡春根，大成基金 阳洪宇 及人员姓名 平安基金 周思聪，宁银理财 徐厚犇 信达证券研究所 唐爱金 时间 2024年2月27日 ...